“Real-world experience and clinical utility of a non-invasive gene expression rule-out test for melanoma and additional validation against high risk driver mutations in BRAF, NRAS and the TERT promoter”, J of Skin, vol. 2, p. S69, Dec. 2018, doi: 10.25251/skin.2.supp.69.